BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 08/11/2016
Entire Document
 

 
· the costs of the development and expansion of our operational infrastructure;
 
· the costs and timing of obtaining regulatory approval of our therapeutic candidates;
 
· the ability of our collaborators to achieve development milestones, marketing approval and other events or developments under our collaboration agreements;
 
· the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
 
· the costs and timing of securing manufacturing arrangements for clinical or commercial production;
 
· the costs of establishing sales and marketing capabilities or contracting with third parties to provide these capabilities for us;
 
· the costs of acquiring or undertaking development and commercialization efforts for any future product candidates;
 
· the magnitude of our general and administrative expenses;
 
· any cost that we may incur under current and future licensing arrangements relating to our therapeutic candidates; and
 
· payments to the OCS.
 
Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through payments received under our collaborations, debt or equity financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, or at all.
 
If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts.
 
Off-Balance Sheet Arrangements
 
Since inception, we have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.
 
14